» Articles » PMID: 31583948

MALDI-TOF Mass Spectrometry-Based High-Throughput Screening for Inhibitors of the Cytosolic DNA Sensor CGAS

Overview
Journal SLAS Discov
Publisher Sage Publications
Specialty Molecular Biology
Date 2019 Oct 5
PMID 31583948
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Comprehensive and unbiased detection methods are a prerequisite for high-throughput screening (HTS) campaigns within drug discovery research. Label-free matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) has been introduced as an HTS-compatible readout for biochemical test systems to support the drug discovery process. So far, reported HTS applications were based on surface-modified systems or proof-of-concept studies. We present the utilization of a MALDI-TOF-based screening platform to identify inhibitors of human cyclic GMP-AMP synthase (cGAS), a mediator of innate immune response whose aberration has been causally correlated to a number of inflammatory disorders. In this context, the development and validation of a MALDI-TOF-based activity assay is reported to demonstrate fast, robust, and accurate detection of chemical cGAS inhibition by direct quantification of the physiological reaction product cyclic GMP-ATP (cGAMP). Results from a screen of a diverse library of more than 1 million small molecules in 1536-well format against the catalytic cGAS activity are presented with excellent assay performance and data quality. Identified hits were qualified in dose-response experiments and confirmed by RapidFire-MS measurements. Conclusively, the presented data provide the first proof of applicability of direct automated MALDI-TOF MS as a readout strategy for large-scale drug discovery HTS campaigns.

Citing Articles

M2ara: unraveling metabolomic drug responses in whole-cell MALDI mass spectrometry bioassays.

Enzlein T, Geisel A, Hopf C, Schmidt S Bioinformatics. 2024; 40(11).

PMID: 39558590 PMC: 11601156. DOI: 10.1093/bioinformatics/btae694.


A whole cell-based Matrix-assisted laser desorption/ionization mass spectrometry lipidomic assay for the discovery of compounds that target lipid a modifications.

Tang W, Osborne J, Dortet L, Larrouy-Maumus G Front Microbiol. 2023; 14:1156795.

PMID: 37138618 PMC: 10149749. DOI: 10.3389/fmicb.2023.1156795.


Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science.

Thamm S, Willwacher M, Aspnes G, Bretschneider T, Brown N, Buschbom-Helmke S J Med Chem. 2023; 66(4):2832-2850.

PMID: 36727857 PMC: 9969402. DOI: 10.1021/acs.jmedchem.2c01884.


Advances in high-throughput mass spectrometry in drug discovery.

Duenas M, Peltier-Heap R, Leveridge M, Annan R, Buttner F, Trost M EMBO Mol Med. 2022; 15(1):e14850.

PMID: 36515561 PMC: 9832828. DOI: 10.15252/emmm.202114850.


Dichlorophenylpyridine-Based Molecules Inhibit Furin through an Induced-Fit Mechanism.

Dahms S, Schnapp G, Winter M, Buttner F, Schleputz M, Gnamm C ACS Chem Biol. 2022; 17(4):816-821.

PMID: 35377598 PMC: 9016704. DOI: 10.1021/acschembio.2c00103.